Patients with neuromyelitis optica have a more severe disease than patients with relapsingremitting multiple sclerosis, including higher risk of dying of a demyelinating disease
Tóm tắt
Although neuromyelitis optica (NMO) is known to be a more severe disease than relapsing-remitting multiple sclerosis (RRMS), few studies comparing both conditions in a single center have been done.Methods:Comparison of our previously published cohort of 41 NMO patients with 177 RRMS patients followed in the same center, from 1994 to 2007.Results:Mean age of onset was 32.6 for NMO and 30.2 for RRMS (p=0.2062) with mean disease duration of 7.4 years for NMO and 10.3 years for RRMS. Patients with NMO had a higher annualized relapse rate (1.0 versus 0.8, p=0.0013) and progression index (0.9 versus 0.6, p≪0.0001), with more patients reaching expanded disability status scale (EDSS) 6.0 (39 versus 17%, p=0.0036). The odds ratio for reaching EDSS 6.0 and being deceased due to NMO in comparison to RRMS were, respectively, 3.14 and 12.15.Conclusion:Patients with NMO have a more severe disease than patients with RRMS, including higher risk of dying of a demyelinating disease.
Từ khóa
Tài liệu tham khảo
Wingerchuk DM, 1999, The clinical course of neuromyelitis optica (Devic's syndrome), Neurology, 53, 1107, 10.1212/WNL.53.5.1107
Bichuetti D, 2009, Neuromyelitis optica in Brazil: a study on clinical and prognostic factors, Mult Scler, 15, 613, 10.1177/1352458508101935
Lana-Peixoto MA, 2008, Devic's neuromyelitis optica: a critical review, Arq Neuropsiquiatr, 66, 120, 10.1590/S0004-282X2008000100034
Jacob A, 2007, Neuromyelitis optica: changing concepts, J Neuroimmunol, 187, 126, 10.1016/j.jneuroim.2007.04.009
Pittock SJ, 2006, Brain abnormalities in neuromyelitis optica, Arch Neurol, 63, 390, 10.1001/archneur.63.3.390
Lim BC, 2011, Relapsing demyelinating CNS disease in a Korean pediatric population: multiple sclerosis versus neuromyelitis optica, Mult Scler, 17, 67, 10.1177/1352458510382685
Wingerchuk DM, 2006, Revised diagnostic criteria for neuromyelitis optica, Neurology, 66, 1485, 10.1212/01.wnl.0000216139.44259.74
Bichuetti DB, 2010, Neuromyelitis optica treatment: analysis of 36 patients, Arch Neurol, 67, 1131, 10.1001/archneurol.2010.203
Oliveira EML, 2006, Multiple sclerosis in Brazil: 1994-2005, a Brazilian experience., S124
McDonald WI, 2001, Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, Ann Neurol, 50, 121, 10.1002/ana.1032
Poser CM, 1983, New diagnostic criteria for multiple sclerosis: guidelines for research protocols, Ann Neurol, 13, 227, 10.1002/ana.410130302
Wingerchuk DM, 2007, A secondary progressive clinical course is uncommon in neuromyelitis optica, Neurology, 68, 603, 10.1212/01.wnl.0000254502.87233.9a
Bichuetti DB, 2008, White matter spectroscopy in neuromyelitis optica: a case control study, J Neurol, 255, 1895, 10.1007/s00415-009-0940-0
Aboul-Enein F, 2010, Diffuse white matter damage is absent in neuromyelitis optica, AJNR Am J Neuroradiol, 31, 76, 10.3174/ajnr.A1791
Bergamaschi R, 2004, Devic's neuromyelitis optica: clinical features and prognostic factors, Neurol Sci, 25, S364, 10.1007/s10072-004-0342-0
Rivera JF, 2008, Characteristics of Devic's disease (neuromyelitis optica) in Mexico, J Neurol, 255, 710, 10.1007/s00415-008-0781-2
Collongues N, 2010, Neuromyelitis optica in France: a multicenter study of 125 patients, Neurology, 74, 736, 10.1212/WNL.0b013e3181d31e35
Brum DG, 2010, HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis, Mult Scler, 16, 21, 10.1177/1352458509350741
Blanco Y, 2010, [Clinical spectrum associated with aquaporin-4 antibodies (NMO-IgG)], Neurologia, 25, 5
Ghezzi A, 2004, Clinical characteristics, course and prognosis of relapsing Devic's neuromyelitis optica, J Neurol, 251, 47, 10.1007/s00415-004-0271-0
Wingerchuk DM, 2003, Neuromyelitis optica: clinical predictors of a relapsing course and survival, Neurology, 60, 848, 10.1212/01.WNL.0000049912.02954.2C
Papais-Alvarenga RM, 2008, Clinical course of optic neuritis in patients with relapsing neuromyelitis optica, Arch Ophthalmol, 126, 12, 10.1001/archophthalmol.2007.26
Papais-Alvarenga RM, 2002, Optic neuromyelitis syndrome in Brazilian patients, J Neurol Neurosurg Psychiatry, 73, 429, 10.1136/jnnp.73.4.429
Adoni T, 2010, Recurrent neuromyelitis optica in Brazilian patients: clinical, immunological, and neuroimaging characteristics, Mult Scler, 16, 81, 10.1177/1352458509353651
Nakashima I, 2006, Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG, J Neurol Neurosurg Psychiatry, 77, 1073, 10.1136/jnnp.2005.080390
Bichuetti DB, 2008, Neuromyelitis optica: brain abnormalities in a Brazilian cohort, Arq Neuropsiquiatr, 66, 1, 10.1590/S0004-282X2008000100001
Costanzi C, 2011, Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica, Neurology, 77, 659, 10.1212/WNL.0b013e31822a2780
Jacob A, 2008, Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients, Arch Neurol, 65, 1443, 10.1001/archneur.65.11.noc80069
Sellner J, 2010, EFNS guidelines on diagnosis and management of neuromyelitis optica, Eur J Neurol, 17, 1019, 10.1111/j.1468-1331.2010.03066.x
Matiello M, 2010, HLA-DRB1*1501 tagging rs3135388 polymorphism is not associated with neuromyelitis optica, Mult Scler, 16, 981, 10.1177/1352458510374340